Verma Ravinder, Bhatia Manisha, Mojumder Mithun, Patel Suraj, Mishra Vivek Kumar, Mathur Pooja, Bhatt Shailendra, Sharma Jai Bharti
Department of Pharmaceutical Sciences, Chaudhary Bansi Lal University, Bhiwani-127021, India.
MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India.
Pharm Nanotechnol. 2024 Sep 26. doi: 10.2174/0122117385307184240826041920.
The potential use of nanoparticle-based formulations is being explored rapidly for drug delivery in ocular treatment. Despite having several advancements in the area of ocular therapy, the pharmacokinetics-based formulation development for pediatric ocular treatment is still not in proper focus. There are an inadequate number of degenerative ocular ailments with childhood onset. The purpose of this review is to focus on the pharmacokinetics studies of nanoparticle- based formulations for treating ocular diseases and problems associated with the ocular treatment of the pediatric population. Recent studies on pharmaceutical modeling of ocular formulations have also been discussed. Nanoparticle-based formulations were collected by conducting a literature survey on PubMed, Science Direct, and other portals. In this review, we have explored in detail the explanation behind the inequality among available ocular treatment regimens for youngsters as well as adults by specifically focusing on those diseases that can be distressing for children. Latest innovative developments and advancements in drug delivery systems and challenges in their usage particularly for young infant patients were also discussed. It can be concluded that the bioavailability of ocular formulations and their effect on ocular cells can be further enhanced manifolds by the development of nanoparticles-based formulations.
基于纳米颗粒的制剂在眼部治疗药物递送方面的潜在应用正在迅速探索。尽管眼部治疗领域有多项进展，但基于药代动力学的儿科眼部治疗制剂开发仍未得到应有的重视。儿童期发病的退行性眼部疾病数量不足。本综述的目的是关注用于治疗眼部疾病以及与儿科人群眼部治疗相关问题的基于纳米颗粒制剂的药代动力学研究。还讨论了眼部制剂药物建模的最新研究。通过在PubMed、Science Direct和其他平台上进行文献调查收集了基于纳米颗粒的制剂。在本综述中，我们通过特别关注那些可能困扰儿童的疾病，详细探讨了青少年和成人现有眼部治疗方案不平等背后的原因。还讨论了药物递送系统的最新创新发展和进步以及它们在使用中面临的挑战，特别是对于年幼婴儿患者。可以得出结论，通过开发基于纳米颗粒的制剂，眼部制剂的生物利用度及其对眼部细胞的作用可以进一步大幅提高。
